This trial is a registrational Phase II/III randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1/VEGF bispecific antibody in first-line patients with locally advanced or metastatic squamous non-small cell lung cancer.
Voluntarily sign the informed consent form and comply with the protocol requirements;
Age ≥18 years;
Expected survival time ≥3 months;
Patients with locally advanced or metastatic squamous non-small cell lung cancer;
Prior histological or cytological evidence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;
Indications of the presence of EGFR-sensitive mutations, among others;
Patients who have received prior systemic therapy;
Prior treatment with agents targeting the mechanism of tumor immune action;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator